All In MedTech

FDA Clearance Tracker · P200015-S077

SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 27, 2026

Approved

Time to decision

180 days

Received Apr 30, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

The decision

FDA number
P200015-S077
Device name
SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
Applicant location
Irvine, CA
Received
Apr 30, 2026
Decided
Oct 27, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P200015

Device type

Every decision under product code NPV

FDA's approval statement

As written in FDA's record.

Approval for a design modification to the outflow apices of the Alterra prestent.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.